Case Investigations

Supreme Industries, Inc.

November 17, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Supreme Industries, Inc. ("Supreme Industries” or the "Company") (NYSE: STS) for potential violations of the federal securities laws.  Investors who purchased Supreme Industries securities may be affected.

InfuSystem Holdings, Inc.

November 17, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating InfuSystem Holdings, Inc. ("InfuSystem” or the "Company") (NYSE: INFU) for potential violations of the federal securities laws.  Investors who purchased InfuSystem securities may be affected.

Diplomat Pharma, Inc.

October 26, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Diplomat Pharmacy, Inc. ("Diplomat” or the "Company") (NYSE: DPLO) for potential violations of the federal securities laws.  Investors who purchased Diplomat securities may be affected.

Trinity Biotech plc

October 19, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Trinity Biotech plc. ("Trinity” or the "Company") (NASDAQ: TRIB), a company developing medical diagnostics products, for potential violations of the federal securities laws.  Investors who purchased Trinity’s American Depositary Receipts (“ADRs”) between December 17, 2015 and October 3, 2016 may be affected.

Opus Bank

October 19, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Opus Bank (“Opus”) (NASDAQ: OPB) for potential violations of the federal securities laws.  Investors who purchased Opus Bank securities between February 26, 2015 and October 18, 2016 (the “Class Period”) may be affected.

Ferrellgas Partners, L.P.

October 11, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Ferrellgas Partners, L.P. ("Ferrellgas” or the "Company") (NYSE: FGP) for potential violations of the federal securities laws.  Investors who purchased Ferrellgas securities between June 1, 2015 and September 28, 2016 (the “Class Period”) may be affected.

Centene Corp.

August 31, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Centene Corp. (“Centene” or the "Company") (NYSE: CNC).  Investors who purchased Centene securities between June 17, 2016 and July 25, 2016 may be affected.

Immunomedics, Inc.

June 3, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Immunomedics, Inc. (“Immunomedics” or the “Company”) (Nasdaq: (IMMU).  Investors who purchased Immunomedics securities between May 4, 2016 and June 2, 2016 may be affected.

Credit Acceptance Corporation

May 4, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Credit Acceptance Corporation ("Credit Acceptance” or the "Company") (NASDAQ: CACC), a subprime auto lender, for potential violations of the federal securities laws.  Investors who purchased shares of Credit Acceptance common stock may be affected.

Natus Medical Incorporated

April 10, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Natus Medical Incorporated (“Natus” or the "Company") (Nasdaq: BABY).  Investors who purchased Natus securities between October 15, 2015 and April 1, 2016 may be affected.

LPL Financial Holdings Inc.

March 30, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating LPL Financial Holdings Inc. (“LPL” or the “Company”) on behalf of investors who purchased LPL securities between December 8, 2015 and February 11, 2016.

GAIN Capital Holdings, Inc.

March 16, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating GAIN Capital Holdings, Inc. (“Gain” or the "Company") (NYSE: GCAP).  Investors who purchased Gain securities between February 27, 2014 and March 15, 2016 may be affected.

Aequitas Management LLC

March 10, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Oregon-based Aequitas Management LLC (“Aequitas” or the "Company").  On March 10, 2016, the U.S. Securities and Exchange Commission (“SEC”) charged Aequitas and three senior executives “with hiding the rapidly deteriorating financial condition of its enterprise while raising more than $350 million from investors."

Match Group, Inc.

February 3, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Match Group, Inc. (“Match” or the “Company”) (Nasdaq: MTCH) for potential violations of the federal securities laws.  Investors who purchased the Company’s common stock since the Company’s initial public offering of common stock on November 18, 2015 at $12 per share on may be affected.

Cnova NV

January 25, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Cnova NV ("Cnova” or the "Company") (Nasdaq: CNV) for potential violations of the federal securities laws.  Investors who purchased Cnova securities may be affected.

Fifth Street Asset Management, Inc.

January 12, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Fifth Street Asset Management, Inc. (“FSAM” or the “Company”) (NASDAQ: FSAM).  FSAM is a credit-focused asset manager and the investment advisor for Fifth Street Finance Corp. (“FSC”), Fifth Street Senior Floating Rate Corp. (“FSFR”), and various private Fifth Street funds. Investors who purchased shares of FSAM common stock in the Company’s October 29, 2014 initial public offering (“IPO”) or since the IPO may be affected.

Anavex Life Sciences Corporation

December 29, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Anavex Life Sciences Corporation (“Anavex” or the “Company”) (Nasdaq: AVXL) for potential violations of the federal securities laws.  Investors who purchased Company securities between October 25, 2015 and December 28, 2015 may be affected.

KaloBios Pharmaceuticals, Inc.

December 21, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating KaloBios Pharmaceuticals, Inc. ("KaloBios” or the “Company”) (NASDAQ: KBIO) for potential violations of the federal securities laws.  Investors who purchased KaloBios’ common stock may be affected.

Neothetics, Inc.

December 15, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Neothetics, Inc. (“Neothetics” or the “Company”) (NASDAQ: NEOT).  Neothetics is a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market. The Company’s lead product candidate, LIPO-202, is for the reduction of subcutaneous fat in the central abdomen (belly fat) in non-obese patients.  Investors who purchased shares of Neothetics common stock in the Company’s initial public offering (“IPO”) or since the IPO may be affected.

Barnes & Noble Education, Inc.

December 11, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Barnes & Noble Education, Inc. ("Barnes & Noble Education” or the "Company") (NYSE: BNED) for potential violations of the federal securities laws.  Investors who acquired or purchased Barnes & Noble Education securities since the Company’s August 2015 spin-out from Barnes &  Noble, Inc. (“Barnes & Noble”) may be affected.

United Development Funding IV

December 11, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating United Development Funding IV ("UDF IV" or the "Company") (Nasdaq: UDF), a Real Estate Investment Trust ("REIT"), for potential violations of the federal securities laws.  Investors who purchased UDF IV securities may be affected.

XBiotech, Inc.

November 24, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating XBiotech, Inc. ("XBiotech” or the "Company") (Nasdaq: XBIT) for potential violations of the federal securities laws.  Investors who purchased XBiotech securities since the Company’s April 14, 2015 initial public offering (“IPO”) may be affected.

Checkpoint Systems, Inc.

November 3, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Checkpoint Systems, Inc.. ("Checkpoint” or the "Company") (NYSE: CKP) for potential violations of the federal securities laws.  Investors who purchased Checkpoint securities may be affected.

Sonic Corp.

June 23, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating the Oklahoma City-based burger chain Sonic Corp (“Sonic”) (Nasdaq: SONC) for potential violations of the Federal Securities Laws. Purchasers of Sonic common stock between January 6, 2015 and June 22, 2015 may be affected.

St. Joseph Health System

San Francisco – February 14, 2014 - Kaplan Fox Investigates Claims Involving A Cyber Security Attack at St. Joseph Health System in Bryan, Texas.

AHMC Healthcare, Inc.

San Francisco – January 9, 2014 - Kaplan Fox & Kilsheimer LLP (“Kaplan Fox”) (www.kaplanfox.com) is investigating potential claims involving the theft of two laptops on October 12, 2013 from a secured office of AHMC Healthcare Inc....

Revel Casino Hotel

San Francisco – October 11, 2013 - Kaplan Fox & Kilsheimer LLP is investigating potential claims that the offer made to consumers by Revel Entertainment Group and Chatham Asset Management in the "Refund All Slot Losses" campaign, effective during the month of July, 2013 at the Revel Casino Hotel in Atlantic City, was misleading and deceptive.

Adobe Systems, Inc.

San Francisco – October 11, 2013 - Kaplan Fox & Kilsheimer LLP is investigating potential claims involving Adobe Systems Inc.’s public announcement on October 3, 2013 that it had discovered “sophisticated attacks” on its network, “involving the illegal access of customer information."

Crestor® (rosuvastatin calcium)

May 25, 2012 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating the statin drug Crestor® (rosuvastatin), a cholesterol-lowering medication, approved by the Food and Drug Administration for use by the public in August 2003.